Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03111446
Other study ID # SpinalHELLP
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 15, 2017
Est. completion date January 1, 2018

Study information

Verified date April 2017
Source Assiut University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Anesthesia for caesarian section in patients with HELLP syndrome is a challenge. Measures should be taken during caesarian delivery to guard against the maternal and fetal complications associated with HELLP syndrome.


Description:

The choice of anesthesia for caesarian section in parturient with HELLP syndrome is a debate. The low platelet count, associated with HELLP syndrome, has often favored the choice of general anesthesia for the caesarian delivery of these parturient. However, general anesthesia in such cases; is not a risk-free approach. General anesthesia is associated with increased risk of difficult airways, stress response to intubation and aspiration. It is also thought to have an effect on the fetus with the potential placental transfer of inhalational anesthetics prior to delivery.

Regional anesthesia is widely regarded as a means of providing analgesia for cesarean section.it also avoids the above-mentioned risks associated with general anesthesia. Regional anesthesia for caesarian section in patients with HELLP syndrome has been used by some researchers in many centers with encouraging results.

The lowest platelet count at which one can safely administer neuraxial anesthesia for labour and delivery is controversial. Published studies are few and sample sizes small.

Criteria developed at the University of Mississippi, as of 2006: "For a patient to merit a diagnosis of HELLP syndrome, class 1 requires severe thrombocytopenia (platelets ≤50,000/μl), evidence of hepatic dysfunction (AST and/or ALT ≥70 IU/l), and evidence suggestive of hemolysis (total serum LDH ≥600 IU/l); class 2 requires similar criteria except thrombocytopenia is moderate (>50,000 to ≤100,000/μl); and class 3 includes patients with mild thrombocytopenia (platelets >100,000 but ≤150,000/μl), mild hepatic dysfunction (AST and/or ALT ≥40 IU/l), and hemolysis (total serum LDH ≥600 IU/L).

The researchers chose to investigate class 2 HELLP syndrome as class 3 proved to be safe with regional anesthesia while class 1 seemed to be high risk and un-ethical to do spinal anesthesia with very low platelets count with lack of any evidence to its safety.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date January 1, 2018
Est. primary completion date December 1, 2017
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria:

Patients with class (II) (12) HELLP syndrome scheduled for elective caesarian section:

Diagnosis of HELLP syndrome was based on the clinical diagnosis of preeclampsia and the following laboratory abnormalities (13):

1. Hemolysis: characteristic peripheral blood smear, serum lactic dehydrogenase (LDH) = 600 U/ l, total bilirubin = 1.2 mg /dl, decreased hemoglobin and hematocrit.

2. Elevated liver enzymes, defined as aspartate aminotransferase (AST). = 70 U/ l, alanin aminotransferase (ALT) = 50 U/ l and lactate dehydrogenase (LDH) = 600 U/ l.

3. Low platelet count: class 2 HELLP having a platelet nadir between > 50000 and 100000 mm-3.

Exclusion Criteria:

1. Emergency cases

2. Placenta praevia

3. Cardiovascular or cerebrovascular disease.

4. Morbid obesity with a BMI =40

5. Gestational age <36 or >41 weeks

6. Platelet counts less than 50000 mm-3; class 1 HELLP and class 3 HELLP having platelet count more than 100 000 mm-3

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Spinal Anesthesia
Spinal needle 25G with Quincke's bevel will be used. It will be induced with a total of 10 mg of 0.5% hyperbaric bupivacaine and 20 mcg fentanyl (total volume 2.4 ml) at the L3-4 interspace. The parturient will be returned to the supine position with a left lateral tilt of 15° to facilitate left uterine displacement. The upper sensory block level will be checked 5 min after the spinal injection by assessing the loss of cold sensation from alcohol swabs, to ensure that a Th6 sensory block level has been achieved.
General Anesthesia
Pre-oxygenation with oxygen 100% via a tight fitting mask rapid sequence technique. Induction is by thiopental (5 mg kg lean body weight) and succinylcholine1.5 mg kg body weight), cricoid pressure should be applied before consciousness is lost and kept in place until confirmation of tracheal intubation with capnography and the cuff of the tracheal tube is inflated. Auscultating the chest helps exclude endobronchial intubation. At this point, surgery may commence.

Locations

Country Name City State
Egypt Assiut university hospital, Faculty of medicine Assiut

Sponsors (1)

Lead Sponsor Collaborator
Assiut University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary The incidence of perioperative mortality in both groups. Maternal up to one week postoperative
Secondary occurence bradycardia heart rate less than 50 beat/min up to 24 hours postoperative
Secondary occurrence of tachycardia heart rate more than 120 beats/min up to 24 hours postoperative
Secondary occurrence of hypotension mean arterial blood pressure < 40% of the baseline up to 24 hours postoperative
Secondary occurrence of hypertension mean arterial blood pressure > 40% of the baseline up to 24 hours postoperative
Secondary incidence of cerebral hemorrhage detected by CT in patients with neurological deficits up to one week postoperative
See also
  Status Clinical Trial Phase
Recruiting NCT03605511 - TTP and aHUS in Complicated Pregnancies
Completed NCT02911701 - Effect of Acetaminophen on Postpartum Blood Pressure Control in Preeclampsia With Severe Features Phase 4
Recruiting NCT02247297 - Pancreatic Stone Protein (PSP) in Pregnant Women
Terminated NCT04725812 - Complement Regulation to Undo Systemic Harm in Preeclampsia Phase 2
Recruiting NCT02020174 - The Preeclampsia Registry
Recruiting NCT06377878 - The Preeclampsia Registry
Recruiting NCT02920593 - A Randomized Control Trial of Vitamin D Prophylaxis in the Prevention of Hypertensive Disorders of Pregnancy Phase 4
Recruiting NCT01138839 - Dexamethasone Efficacy in HELLP I Syndrome Phase 3
Recruiting NCT05500989 - PlacEntal Acute Atherosis RefLecting Subclinical Atherosclerosis
Completed NCT04216706 - Early Vascular Adjustments to Prevent Preeclampsia
Recruiting NCT03834285 - Liver Disease in Pregnancy
Completed NCT00000534 - Calcium for Pre-Eclampsia Prevention (CPEP) Phase 3
Recruiting NCT02807324 - Women Specific Cardiac Recovery After Preeclampsia
Completed NCT01736826 - Free DNA and Nucleosome Concentrations in Pathological Pregnancies
Terminated NCT00711841 - Effectivity of Postpartum Dexamethasone for Women With Class I HELLP Syndrome Phase 4
Completed NCT00097110 - RCT of Antioxidant Therapy to Prevent Preeclampsia in Brazil Phase 3
Completed NCT03715647 - Correlation of Survival in Puerperae by Electrical Impedance Tomography
Completed NCT03455387 - Evaluation of the Serum Markers sFLt1 and PlGF for the Prediction of the Complications of the Placental Vascular Pathologies in the 3rd Quarter of the Pregnancy.
Completed NCT03246542 - Promising Bimarker Prediction of Outcome of HELLP Syndrome. N/A
Completed NCT03232359 - Immature Platelet Fraction as a Promising Biomarker in Prediction Outcome of HELLP Syndrome N/A